元の名称記録: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE; UNIVERSITÉ PARIS CITÉ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

Inventors have explored the relevance of alpelisib in MRL/MpJ-Faslpr/J mice (referred here as MRL-lpr). a mouse model of lupus nephritis. MRL-lpr mice treated with alpelisib demonstrated less proteinuria compared to vehicle. More stinkingly, comparison of albuminuria before and after treatment introduction showed opposite trajectories. Indeed. MRL-lpr mice treated with alpelisib demonstrated proteinuria improvement arguing for a reversibility of the disease. At sacrifice. MRL-lpr mice treated with alpelisib had a tendency to have a lower kidney to body weight ratio compared to vehicle treated animals. Kidney examination showed that alpelisib was associated with no glomerular lesions compared to vehicle treated mice and an improved kidney function. Inventors conclude that alpelisib and more generally PIK3CA inhibition represent promising drugs for patients with proliferative glomerulonephritis. The invention relates to a method for treating proliferative glomerulonephritis in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of a PIK3CA inhibitor.